Table of Contents
ISRN Oncology
Volume 2011, Article ID 670358, 6 pages
http://dx.doi.org/10.5402/2011/670358
Clinical Study

No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma

1Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
2Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
3Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand

Received 15 August 2011; Accepted 18 September 2011

Academic Editor: G. Schiavon

Copyright Β© 2011 Pairaya Rujirojindakul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to determine the clinical significances of p53 and p-glycoprotein (P-gp) expression on outcome predictors for patients with DLBC. We assessed the immunohistochemical expression of p53 and P-gp using formalin-fixed, paraffin-embedded specimens in 108 patients diagnosed with de novo DLBC. A high expression of p53 was found in 53.7% of the patients. No expression of P-gp was demonstrated in any of the specimens. There were no significant differences in the complete remission (CR) rate ( 𝑃 = 0 . 7 9 ), overall survival (OS) ( 𝑃 = 0 . 7 3 ), or disease-free survival (DFS) ( 𝑃 = 3 1 ) between the p53-positive and p53-negative groups. The final model from multivariate analysis that revealed poor performance status was significantly associated with CR ( 𝑃 < 0 . 0 0 1 ) and OS ( 𝑃 < 0 . 0 0 1 ). Moreover, the advanced stage was a significant predictor of DFS ( 𝑃 = 0 . 0 3 ). This study demonstrated no impact of the expression of p53 on either response or survival rates.